The diagnosis of anaphylaxis during anaesthesia is usually based on case history, skin testing, radioimmunoassays (RIAs) for drug-specific IgE antibodies and, less often, leucocyte or basophil histamine release studies. 1.2 Skin and histamine release tests require a living patient, and IgE RIAs with pre-reaction blood have been used to confirm the diagnosis in patients who have died. 3 . 4 This has epidemiological and medicolegal value, particularly as post mortem findings in anaphylaxis are relatively non-specific, 5 and in two cases described previously the use of such tests led to a change in the coronial diagnosis. 4 Recently, a commercial RIA for mast cell tryptase has been introduced and this test appears highly specific for anaphylaxis and reactions related to release of histamine from mast cells by other mechanisms. 6.7 It has further been shown that tryptase levels were elevated in 17 of 19 patients who died of anaphylaxis, but not in sera from six patients who died of other causes. The blood in these studies was taken up to 24 hours post mortem. 8 Mast cell tryptase assays give no information about the agent responsible for the reaction.
In this communication we describe investigations on tryptase and drug-reactive IgE antibodies in the sera of two patients who died of anaphylaxis during anaesthesia, In one of the patients, blood was taken both preoperatively and three days post mortem.
CASE REPORTS

Case 1
The patient was a 51-year-old invalid pensioner who presented with pain in the elbow and was scheduled for removal of the right radial head. She had a past history of exposure to eight general anaesthetics and the details of seven of those were available. She had seven uneventful exposures to thiopentone and pancuronium, while vecuronium and alcuronium had been received uneventfully once and suxamethonium uneventfully on two occasions.
The subject, who smoked two packets of cigarettes a day, had a history of allergy to codeine and Elastoplast and a past medical history of hypertension for which she took atenolol 50 mg daily. She was also on bendrofluazide 5 mg, ranitidine 150 mg b.d., clonazepam 2 mg nocte, ketoprofen 2 mg nocte, Gaviscon® 1 Ld.s., nitrazepam 5 mg nocte and had a history of heart failure. She was premedicated with pethidine 100 mg and atropine 0.6 mg, induced with thiopentone 315 mg and vecuronium 8 mg and manually ventilated with nitrous oxide and oxygen. Immediately she was noted to be difficult to ventilate and the nitrous oxide was discontinued. She became bradycardic and hypotensive and there was no response to atropine 0.6 mg. CPR was commenced and the patient was given over the next 45 minutes 100 ml 8.4070 sodium bicarbonate, 1 ml of 1:1000 adrenaline and 40 ml of 1:10,000 adrenaline, a further 0.4 mg atropine, 50 mg of sotalol, 1000 ml of stable plasma protein solution 5070 and 500 mllactated Ringer's solution. Her rhythm varied between slow ventricular fibrillation and bradycardia and she was defibrillated on three occasions unsuccessfully. Forty-five minutes after induction the subject was pronounced dead. At autopsy, performed three days later, "pulmonary oedema and congestion, a flabby myocardium with dilation of both ventricles, and a small area of mottling in the posteroseptal region of the left ventricle" were found. Blood taken at this time and blood taken preoperatively were provided to our laboratory.
Case 2
This patient was a 60-year-old man with a past history of narcolepsy for which he took amphetamines. The patient presented with complaints of deteriorating eyesight, and history of chronic tiredness for which he was scheduled for cervical spine manipulation under general anaesthesia in a private clinic. He had an anaesthetic history of two previous exposures. After the second, some 20 years before at a hospital he could not identify, he had a severe reaction and was informed he was allergic to thiopentone. A preoperative electrocardiograph (ECG) was normal. He was given atropine 0.6 mg IV and induced with propofol 200 mg and suxamethonium chloride 75 mg and intubated without difficulty. Within three minutes the patient was cyanosed, the ECG monitor showed asystole and his pupils became fixed and dilated. He was given adrenaline 1.0 ml of 1:1000 IV and defibrillated but remained pulseless in asystole. A further three injections of adrenaline 1:1000 1.0 ml followed by defibrillation were unsuccessful. Paramedics were called who administered 8.4070 sodium bicarbonate 50 ml, calcium chloride 1.0 g and two further attempted defibrillations were unsuccessful. He was transported to hospital and external cardiac massage was continued. On arrival he was still asystolic and after further adrenaline and defibrillation he was pronounced dead one hour and eight minutes after induction.
Autopsy showed a mildly dilated heart with 50070 stenosis of the left anterior descending coronary artery, 70070 distal stenosis of the left circumflex coronary artery and 30-40070 stenosis of the right coronary artery and congestion of both lungs. Blood was taken at the time of autopsy 48 hours after death and sent to our laboratory.
LABORATORY METHODS AND RESULTS
Mast cell tryptase levels were measured using the Pharmacia Tryptase RIA kit. 9 Serum samples, from blood taken preoperatively from Case 1 and at autopsy from Case 1 and Case 2, were examined. Control blood was taken three days after death from two patients who had died from other causes (acute alcoholism and ruptured abdominal aortic aneurysm).
RIAs for drug-specific IgE to thiopentone and neuromuscular blocking drugs (NMBDs) and RIA inhibition studies were carried out using methods previously described. Ill" RIA inhibition is used to verify RIA results, and to separate false positive results for thiopentone which occur in NMBD reactors. 15 Table 1 shows the results of mast cell tryptase assays in the two patients and controls. There were clear-cut elevated levels in the sera from patients but not in the control sera, demonstrating that mast cell activation occurred during the reaction and prior to death. Table 2 shows the results of RIAs for drug-reactive IgE antibodies found in the sera of patients and controls. In Case 1, positive assays for thiopentone and alcuronium were obtained in preoperative and postoperative specimens, while d-tubocurarine was positive in the preoperative and equivocal in the postoperative sera. In serum from Case 2, positive tests were found for thiopentone and all the NMBDs tested. There were no positive reactions detected in the control sera. RIA inhibition studies of the thiopentone RIA with the preoperative serum sample from Case 1 showed 50070 inhibition with 6.5 nmol of thiopentone, confirming the presence of IgE specific for this drug AnaeSlhe.sia and Intensive Care, Vol. 21, /'v'o. 3, June, 1993 ( Figure 1 ). Very weak inhibition was observed with alcuronium and vecuronium. 15 When the alcuronium RIA was employed in inhibition studies (Figure 2 ), clear inhibition (50070 inhibition with only 4.3 nmol) was observed with alcuronium, suggesting a true IgEmediated reaction to this drug. Inhibition with vecuronium was less potent (68 nmol for 50070 inhibition) and only one other NMBD, gallamine (> 50070 inhibition with 1000 nmol), showed any inhibitory activity. Very similar results were obtained when the post mortem serum sample from Case 1 was used in RIA inhibition studies with the thiopentone-and alcuronium-solid phases.
TABLE 1
Mast cell serum tryptase levels in patients and controls
With serum from Case 2, the thiopentone RIA could not be inhibited by thiopentone, suggesting in vitro cross-reactivity with the NMBDs which does not have a clinical expression. 15 Figure 3 shows the inhibition findings using serum from Case 2 in the cholinesepharose assay for suxamethonium-reactive IgE antibodies. Clear-cut inhibition with suxamethonium and vecuronium was observed, suggesting the presence of IgE antibodies with combining sites highly complementary to these two drugs. d-tubocurarine and alcuronium were much less potent inhibitors (Table 3) , while thiopentone showed no significant inhibition (Figure 3 ). Serum was used at a dilution of 1-120. Key to symbols: 0 suxamethonium; • alcuronium; Dd-tubocurarine; • vecuronium; f\, thiopentone.
RIA inhibition studies with post mortem serum from Case 2. Findings with NMBDs and thiopentone using choline-solid phase
DISCUSSION
From a careful consideration of the clinical observations and all the immunoassay results we concluded that Case 1 died from an anaphylactic reaction to thiopentone, with the possibility of concurrent allergy to vecuronium, and Case 2 died of anaphylaxis to suxamethonium.
In these two cases we have shown that post mortem bloods are valuable in diagnostic tests for anaphylaxis induced by anaesthetic drugs. These tests have previously been used with blood taken up to 24 hours after fatal anaphylaxis to foodstuffs 8 and we have now shown that specimens taken up to three days post mortem are also suitable for aiding the diagnosis.
Evaluation of serum tryptase levels is optimal one to six hours after a reaction commences since the enzyme may not be elevated in the first 30 minutes after a reaction. For the test to be useful then, the patient must survive for at least thirty minutes. '.H. 16 Interestingly, in Case 2, cardiac arrest occurred early and it appears that continuing attempts at resuscitation allowed time for the tryptase level to rise.
In the published studies, elevated mast cell tryptase levels have not been found in conditions other than anaphylactoid reactions. Patients have been described, however, both in reactions to anaesthetic drugs 7 and foods 17 in which expected elevated levels were not found. The reason for such results may include sampling outside the "time window" for elevated levels, or mechanisms of anaphylaxis involving cells which do not contain tryptase such as basophils .. ,.
In both of these cases, which involved cardiovascular manifestions, the diagnosis of anaphylaxis was not obvious clinically or at autopsy. Under these circumstances the investigations we employed have obvious epidemiological and medicolegal significance.
The employment of RIAs to determine the drug responsible illustrates a number of the difficulties with the interpretation of these assays. Firstly, both patients showed positive RIAs for thiopentone which may occur in up to 20070 of patients who are allergic to NMBDs. This in vitro cross-reactivity can be distinguished from a true positive to thiopentone using RIA inhibition where sera from the false positives cannot be inhibited by thiopentone. 15 Thus, with Case 1, where the thiopentone RIA was easily inhibited by thiopentone, we can confidently conclude that the subject experienced a true type 1, IgE-mediated reaction to the induction agent. This conclusion for Case 1 correlated with the usual history of six or more previous exposures to the drug. 18 With Case 2, however, the failure of thiopentone to inhibit IgE antibody binding to thiopentone-Sepharose showed that the subject was not allergic to this drug and reaction with the thiopentone-solid phase was due to cross-reacting NMBD-reactive IgE antibodies. 15 With the direct RIAs for NMBDs, the detection of positives is rare in patients who have not reacted to an NMBD. However, it is not uncommon for a positive RIA to occur to a drug other than the one given prior to the reaction, 19 and this is related to the common allergenic determinant, that is, the quaternary or tertiary ammonium group shared by all NMBDs.20.2 1 As with thiopentone, the validity of the direct RIA can be confirmed by demonstrating inhibition at low levels, which gives a better correlation with exposure and skin tests than RIA results alone. 19.20 Thus with Case 1 the significant uptake and inhibition with alcuronium suggest the patient was also allergic to this drug, but the significant inhibitions, and thus cross-reactivity, seen with vecuronium (the drug administered) does not allow us to say with certainty that this drug was also involved. 22 In Case 2, the RIA to suxamethonium which was easily inhibited showed true IgE-mediated allergy to suxamethonium and the strong inhibition observed with vecuronium suggested that allergic sensitivity to this NMBD was also likely.
The results of RIA determinations with blood taken at the time of a reaction correlate well with blood taken subsequently 23 and results with Case 1 suggest that post mortem samples may also correlate well with blood taken preoperatively or at the time of a reaction. Case 2 illustrates a further important point with respect to anaesthetic anaphylaxis. With skin testing and RIA testing we were able to diagnose the drug responsible in four patients with a history of a reaction over twenty years before, and this ensured safe subsequent anaesthesia '4 in patients who gave a history of allergy to an anaesthetic drug without supporting documentation. Case 2 illustrates that it is prudent to undertake at least skin testing prior to elective surgery rather than accept a poorly documented history at face value. This patient is the third death in our series where anaesthetic drug selection based on invalid information and assumption, rather than investigation, was followed by anaphylaxis. However, in the majority of such patients referred with such a history, nothing is found and subsequent anaesthesia is uneventful.
In conclusion, these results emphasise the value of serum mast cell tryptase determinations and RIA tests for drug-reactive IgE antibodies on post mortem blood in determining the dangers of and drug responsible for fatal anaphylaxis during anaesthesia. In cases where anaphylaxis is a possible cause of an adverse event, blood taken prior to the reaction, during the reaction or at autopsy should be analysed to determine the nature of the reaction.
